The Use of Nonhuman Primate Models in HIV Vaccine Development
article has not abstract
Vyšlo v časopise:
The Use of Nonhuman Primate Models in HIV Vaccine Development. PLoS Med 5(8): e173. doi:10.1371/journal.pmed.0050173
Kategorie:
Guidelines and Guidance
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.0050173
Souhrn
article has not abstract
Zdroje
1. DesrosiersRC
2004
Prospects for an AIDS vaccine.
Nat Med
10
221
223
2. FeinbergMBMooreJP
2002
AIDS vaccine models: Challenging challenge viruses.
Nat Med
8
207
210
3. HaigwoodNL
2004
Predictive value of primate models for AIDS.
AIDS Rev
6
187
198
4. HuSL
2005
Non-human primate models for AIDS vaccine research.
Curr Drug Targets Infect Disord
5
193
201
5. JohnsonRP
2006
HIV pathogenesis and vaccine development.
Top HIV Med
14
8
15
6. KoffWCJohnsonPRWatkinsDIBurtonDRLifsonJD
2006
HIV vaccine design: Insights from live attenuated SIV vaccines.
Nat Immunol
7
19
23
7. LetvinNL
2006
Progress and obstacles in the development of an AIDS vaccine.
Nat Rev Immunol
6
930
939
8. LifsonJDMartinMA
2002
One step forwards, one step back.
Nature
415
272
273
9. MalkevitchNVRobert-GuroffM
2004
A call for replicating vector prime-protein boost strategies in HIV vaccine design.
Expert Rev Vaccines
3
S105
S117
10. RobinsonHLAmaraRR
2005
T cell vaccines for microbial infections.
Nat Med
11
S25
S32
11. ShiverJWFuTMChenLCasimiroDRDaviesME
2002
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Nature
415
331
335
12. CasimiroDRWangFSchleifWALiangXZhangZQ
2005
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag.
J Virol
79
15547
15555
13. WilsonNAReedJNapoeGSPiaskowskiSSzymanskiA
2006
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.
J Virol
80
5875
5885
14. WyandMSMansonKMontefioriDCLifsonJDJohnsonRP
1999
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.
J Virol
73
8356
8363
15. RobertsonMMehrotraDFitzgeraldDDuerrACasimiroD
2008
Efficacy results from the Step Study (Merck V520 Protocol 023/HVTN 502)—A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent vaccine [abstract 88LB].
15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston, Massachusetts, United States of America. Available: http://www.hvtn.org/science/step_buch.html. Accessed 10 July 2008
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2008 Číslo 8
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Nech brouka žít… Ať žije astma!
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Ensuring the Involvement of Children in the Evaluation of New Tuberculosis Treatment Regimens
- Predicting Outcome after Traumatic Brain Injury: Development and International Validation of Prognostic Scores Based on Admission Characteristics
- The Use of Nonhuman Primate Models in HIV Vaccine Development
- Strategies to Reduce Mortality from Bacterial Sepsis in Adults in Developing Countries